MANGOCEUTICALS INC

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

MGRX$0.20+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	June 30, 2024 (Unaudited)	December 31, 2023
ASSETS
CURRENT ASSETS
Cash	$490,243	$739,006
Inventory	14,019	18,501
Prepaid expenses - related party	13,299	60,953
TOTAL CURRENT ASSETS	517,561	818,460
NON-CURRENT ASSETS
Property and equipment, net of accumulated depreciation of $1,749 and $28,752	3,313	96,129
Right of use - asset	90,011	119,262
Intangible assets – acquired patents	14,610,000	-
TOTAL NON-CURRENT ASSETS	14,703,324	215,391
OTHER ASSETS
Deposits	16,942	16,942
TOTAL OTHER ASSETS	16,942	16,942
TOTAL ASSETS	$15,237,827	$1,050,793
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued liabilities	$718,650	$140,765
Payroll tax liabilities	4,687	6,595
Notes payable to related parties	187,500	-
Right-of-use liability - operating lease	67,428	63,718
Other liabilities – patent purchase payable	400,000	-
TOTAL CURRENT LIABILITIES	$1,378,265	$211,078
LONG-TERM LIABILITIES
Right-of-use liability - operating lease	30,117	64,961
TOTAL LONG-TERM LIABILITIES	30,117	64,961
TOTAL LIABILITIES	$1,408,382	$276,039
COMMITMENTS AND CONTINGENCIES (SEE NOTE 11)	-	-
STOCKHOLDERS’ EQUITY
Series B Convertible Preferred stock, (par value $0.0001, 6,000 shares authorized), of which 2,145 and 0 shares were issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	-	-
Series C Convertible Preferred par value $0.0001, 6,250,000 shares authorized) of which 980,000 and 0 shares were issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	98	-
Common stock (par value $0.0001, 200,000,000 shares authorized, of which 29,135,451 and 21,419,500 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively)	2,913	2,142
Stock warrants	514,496	-
Subscription receivable	(1,000,000)	-
Additional paid in capital	30,300,213	12,000,785
Accumulated deficit	(15,986,733)	(11,228,173)
Accumulated other comprehensive loss	(1,166)	-
TOTAL STOCKHOLDERS’ EQUITY	13,829,821	774,754
Non-controlling interest	(376)
TOTAL STOCKHOLDERS’ EQUITY	13,829,445	774,754
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$15,237,827	$1,050,793

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.